Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.

by Mohamed El Missiry, Henrik Hjorth-Hansen, Johan Richter, Ulla Olson-Strömberg, Leif Stenke, Kimmo Porkka, Anna Kreutzman, Satu Mustjoki
Published 2017-01-01

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia

by Miguel Carracedo, PhD, Leif Stenke, MD, PhD, Anders Franco-Cereceda, MD, PhD, Magnus Bäck, MD, PhD
Published 2020-03-01

Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells

by Alena Malyukova, Dorina Ujvari, Elham Yektaei-Karin, Ana Zovko, Harsha S. Madapura, Marton Keszei, Noemi Nagy, Kourosh Lotfi, Niclas Björn, Jonas Wallvik, Minori Tamai, Thao T. T. Nguyen, Koshi Akahane, Takeshi Inukai, Leif Stenke, Daniel Salamon
Published 2021-09-01

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

by Anna Kreutzman, Bhagwan Yadav, Tim H. Brummendorf, Bjorn Tore Gjertsen, Moon Hee Lee, Jeroen Janssen, Tiina Kasanen, Perttu Koskenvesa, Kourosh Lotfi, Berit Markevärn, Ulla Olsson-Strömberg, Jesper Stentoft, Leif Stenke, Stina Söderlund, Lene Udby, Johan Richter, Henrik Hjorth-Hansen, Satu Mustjoki
Published 2019-09-01